New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
09:11 EDTKSS, VIPS, PRGO, SUPN, ENPH, ARUN, NDLS, RHHBY, SNY, ITMN, DDD, SSYS, VJET, XONE, PLUG, KBIOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
News For KSS;PLUG;XONE;VJET;SSYS;DDD;ITMN;SNY;RHHBY;NDLS;ARUN;ENPH;SUPN;PRGO;VIPS;KBIO From The Last 14 Days
Check below for free stories on KSS;PLUG;XONE;VJET;SSYS;DDD;ITMN;SNY;RHHBY;NDLS;ARUN;ENPH;SUPN;PRGO;VIPS;KBIO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 3, 2014
12:49 EDTSNYSanofi reports Dengue vaccine candidate achieves its phase 3 primary endpoint
Sanofi Pasteur, the vaccines division of Sanofi, announced that the final landmark phase 3 efficacy study of its dengue vaccine candidate in Latin America successfully achieved its primary clinical endpoint. Results showed an overall significant reduction of 60.8% of dengue disease cases in children and adolescents 9-16 years old after a three-dose vaccination schedule. Importantly, efficacy was observed against each of the four dengue serotypes. Additional observations of the results showed a clinically important reduction by 80.3% in the risk of hospitalization due to dengue during the study. The results also showed in the study population an efficacy against dengue haemorrhagic fever, the severe form of dengue, which is consistent with the results released from Sanofiís phase 3 dengue study in Asia. Lastly, the results suggest better protection in case of prior exposure to dengue.
12:33 EDTRHHBYOn The Fly: Midday Wrap
Stocks on Wall Street were higher to begin the day, as reports spurred optimism that a ceasefire agreement between Russia and the Ukraine may soon be reached. The move was short lived, as the averages turned mixed during the second hour of trading. Shares of Apple (AAPL) are weighing down the Nasdaq after an analyst recommended investors take some profits in the stock. ECONOMIC EVENTS: In the U.S., factory orders rose 10.5% in July, which was a bit below the forecast for 11.0% growth. The Fed's Beige Book is scheduled to be released at 2:00 pm ET. In Europe, the final reading of Eurozone services PMI was knocked down to 53.1 from a preliminary 53.5 reading, mirroring the lowering of the Eurozone manufacturing PMI reading yesterday. COMPANY NEWS: Shares of Apple retreated 4% after research firm Pacific Crest advised investors to take some profits in the stock. Pacific Crest analyst Andy Hargreaves forecast the percentage of new iPhone users who buy the next version of the device beyond the iPhone 6 is likely to decline versus prior cycles. The stock likely has only limited room to increase, according to Hargreaves, who said he would probably downgrade Apple unless new products that can generate billions of dollars in new operating profit are launched at its September 9 event... Carmakers reported on August vehicle sales in the U.S., with Chrysler (FIATY) reporting a 20% increase, Ford stating that sales rose slightly compared to the prior year and General Motors (GM) posting a 1.2% decline in sales. MAJOR MOVERS: Among the notable gainers was Infinity Pharmaceuticals (INFI), which jumped 46% after the company announced a cancer drug collaboration with AbbVie (ABBV) and a master clinical supply agreement with Roche (RHHBY). Also higher was Mobileye (MBLY), which gained nearly 10% after Morgan Stanley wrote that the stock could rise "towards $100" if the company maintains its current market, gross margins and earnings position. Mobileye is scheduled to report on its second quarter results tomorrow morning, which will be its first quarterly report since its August IPO. Among the noteworthy losers was Repros Therapeutics (RPRX), which dropped 15% after newly posted FDA briefing documents regarding a panel on T-normalizing therapies prompted Piper Jaffray to downgrade the stock to Neutral from Overweight. Also lower following its earnings report was apparel company Vince Holding (VNCE), which fell 11%. INDEXES: Near midday, the Dow was up 33.71, or 0.2%, to 17,101.27, the Nasdaq was down 23.24, or 0.51%, to 4,574.95, and the S&P 500 was down 0.64, or 0.03%, to 2,001.64.
11:07 EDTARUNOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTKSSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:31 EDTDDD3D Systems acquires LayerWise, terms not disclosed
Subscribe for More Information
07:49 EDTKSSKohl's upgraded to Buy from Hold at Maxim
Subscribe for More Information
07:32 EDTKSSKohl's upgraded to Buy from Hold at Maxim
Subscribe for More Information
07:10 EDTKSSKohl's upgraded to Buy from Hold at Maxim
Subscribe for More Information
07:03 EDTKSSKohl's announces partnership with AwesomenessTV
Subscribe for More Information
06:48 EDTRHHBYInfinity Pharmaceuticals partners with Roche for blood cancer clinical studies
Infinity Pharmaceuticals (INFI) has entered into a master clinical supply agreement with Roche (RHHBY) under which Roche will supply Gazyva to Infinity for use in planned clinical studies to evaluate the combination of Gazyva and duvelisib, Infinityís oral inhibitor of phosphoinositide-3-kinase -delta and PI3K-gamma, in patients with hematologic malignancies, or blood cancers. The companies have also entered into a material transfer agreement under which Infinity is supplying Roche with duvelisib for use in Rocheís preclinical and translational research to evaluate the combination of duvelisib and Gazyva.
06:06 EDTSSYSStratasys to host analyst meeting
Subscribe for More Information
05:48 EDTITMNStocks with implied volatility movement; ITMN EBAY
Subscribe for More Information
September 2, 2014
20:26 EDTSNYSanofi has a conference call hosted by JPMorgan
Subscribe for More Information
15:55 EDTDDD3D Systems initiated with a Buy at Fintrust
Subscribe for More Information
13:58 EDTSNYRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
11:08 EDTARUNOptions with decreasing implied volatilit
Subscribe for More Information
08:45 EDTDDD3D Systems partners with Vortex VR
Subscribe for More Information
08:35 EDTSNYIntrexon enters into ECC with Sanofi subsidiary to develop APIs
Subscribe for More Information
07:21 EDTSNYRegeneron data positive, says RBC Capital
Subscribe for More Information
05:46 EDTSSYSStratasys shares to benefit from second half catalysts, says Piper Jaffray
Piper Jaffray believes second half of 2014 catalysts, including the upcoming Analyst/Investor day, the ramping of new products and consistent execution, should allow shares of Stratasys to continue working higher. Piper reiterates an Overweight rating on the stock with a $145 price target.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use